HER2(human epidermal growth factor receptor 2) -positive metastatic breast cancer in Russia

Study identifier:D133HR00027

ClinicalTrials.gov identifier:NCT05905939

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A multicenter observational retrospective study of therapeutic approaches and clinical outcomes in real clinical practice in Russian patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer

Medical condition

Breast Cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

755

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 31 May 2023
Primary Completion Date: 29 Mar 2024
Study Completion Date: 29 Mar 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria